Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
epublish
Résumé
We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced levels of neutralization by vaccinated and convalescent sera. Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.
Identifiants
pubmed: 33851185
doi: 10.1101/2021.04.04.21254881
pmc: PMC8043482
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI145835
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nat Immunol. 2021 Mar 5;:
pubmed: 33674800
JAMA. 2021 Mar 16;325(11):1037-1038
pubmed: 33595644
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
PLoS One. 2021 Feb 8;16(2):e0246772
pubmed: 33556142
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Cell Rep. 2021 Jan 12;34(2):108630
pubmed: 33417835
Cell Rep. 2021 Feb 16;34(7):108737
pubmed: 33545052
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
Elife. 2020 Oct 28;9:
pubmed: 33112236
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399